Medeon Biodesign (6499) — Cash Flow-to-Debt Ratio
Medeon Biodesign (6499) has a Cash Flow-to-Debt Ratio of -0.47x as of June 2025, meaning its operating cash flow of NT$-133.97 Million could theoretically repay 0% of its total liabilities (NT$284.53 Million) in one year. See Medeon Biodesign free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medeon Biodesign Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Medeon Biodesign across 8 annual periods. Also explore how fast is Medeon Biodesign growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Medeon Biodesign (2017–2024)
Year-by-year debt coverage analysis for Medeon Biodesign. For market capitalisation and broader financial context, see 6499 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.44x | NT$-832.66 Million | NT$341.84 Million | ▼ -21.2% |
| 2023 | -2.01x | NT$-755.08 Million | NT$375.65 Million | ▼ -64.0% |
| 2022 | -1.23x | NT$-461.34 Million | NT$376.48 Million | ▲ +26.5% |
| 2021 | -1.67x | NT$-293.38 Million | NT$176.00 Million | ▼ -634.8% |
| 2020 | -0.23x | NT$-151.27 Million | NT$666.83 Million | ▲ +74.9% |
| 2019 | -0.90x | NT$-241.99 Million | NT$268.18 Million | ▼ -141.7% |
| 2018 | 2.16x | NT$322.05 Million | NT$148.89 Million | ▲ +173.4% |
| 2017 | -2.95x | NT$-310.76 Million | NT$105.41 Million | — |